Tuesday, 19 June 2012

Composition With Potent And Specific Bactericidal Action Against Staphylococcus Aureus And MRSA

The University of St Andrews invention comprises the combination of a cationic peptide with a bacterially-produced endopeptidase. The combination of these two molecules results in specific inhibition of Staphylococcus aureus MRSA or MSSA. 


Their results have shown that a specific and potent bactericidal effect is produced. Furthermore, the combination of the two components is synergistic, requiring far smaller quantities of the two components combined than either individual component to achieve the same degree of efficacy. The synergistic mode of action has the advantage that the two individual components act upon the bacterium by different mechanisms, therefore, it is expected that the combination would help prevent the rapid acquisition of resistance to the individual component antimicrobials. This is of particular importance for bacteria such as Staphylococcus aureus which are usually adept at acquiring resistance. The combination may also prove to be specifically efficacious against Staphylococcus aureus when impregnated into wound dressings or alternatively, used as a coating on medical devices or surgical instruments. The risk of spreading infection may be reduced by spraying or dipping any contact surfaces and medical or surgical instruments in order to disinfect any existing bacterial population or to inhibit bacterial re-colonisation

No comments:

Post a Comment

Note: only a member of this blog may post a comment.